Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.78

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given an average recommendation of “Buy” by the nine ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $34.78.

XNCR has been the topic of a number of research analyst reports. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Xencor in a research report on Monday, September 9th. Royal Bank of Canada boosted their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Xencor in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. cut their price target on Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of XNCR. Quarry LP bought a new stake in shares of Xencor in the second quarter worth approximately $36,000. SG Americas Securities LLC bought a new stake in Xencor in the 2nd quarter worth approximately $154,000. XTX Topco Ltd purchased a new stake in Xencor during the 2nd quarter valued at $196,000. Acadian Asset Management LLC bought a new position in shares of Xencor during the 1st quarter valued at $206,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Xencor in the 2nd quarter worth $212,000.

Xencor Stock Performance

NASDAQ XNCR opened at $21.57 on Friday. The stock has a market cap of $1.33 billion, a PE ratio of -9.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. The firm has a 50-day moving average of $19.51 and a 200-day moving average of $20.10. Xencor has a 52-week low of $15.31 and a 52-week high of $26.84.

Xencor (NASDAQ:XNCR) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The business had revenue of $16.96 million during the quarter, compared to the consensus estimate of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The company’s revenue was down 62.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.37) EPS. On average, sell-side analysts anticipate that Xencor will post -4.11 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.